The presence of excessive amounts of viscous and tenacious mucus secretions in the tracheobronchial region is the most widely known feature of cystic fibrosis (CF). These mucus secretions cause obstruction of the airways and lead to chronic pulmonary disease which dominates the clinical picture and determines the fate of the majority of CF patients. The objective of this research is to investigate the molecular basis of altered viscoelastic properties of CF tracheobronchial secretions.
The specific aims of this proposal are a) to continue isolation, purification and characterization of mucus glycoproteins (mucins) from tracheobronchial secretions of patients with CF, asthma, bronchitis and from normal healthy individuals; b) to investigate the effects of different sodium chloride concentrations on the molecular aggregation, conformation (shape) and viscoelastic properties of purified CF and non-CF mucins; c) to investigate the biochemical properties of integral polypeptides released upon disulfide bond reduction of purified native CF and non-CF mucins; and d) to isolate and characterize mucin species present in the purified mucins prepared from CF and non-CF secretions. The mucins will be purified using protocols established in this laboratory. The mucin species (from purified CF and non-CF mucins) will be isolated by anion-exchange and immunoaffinity chromatographies. The isolated mucins as well as various mucin species from the CF and non-CF secretions will be characterized for their biochemical, biophysical and immunological properties. Biochemical characterization will include: determination of carbodrate, sulfate, amino acid composition, thiol and dissulfide bond content of the mucin molecules. The molecular size, conformation and aggregation properties will be investigated using state-of-the-art techniques, such as, static light scattering and fluorescence polarization techniques. The viscoelastic studies will be conducted using a magnetic microrheometer. The structure of the protein cores of the mucin will be investigated by immunological and biochemical methods. These studies will aid in the understanding of mechanism(s) responsible for altered viscoelastic properties of CF tracheobronchial secretions. This knowledge will be essential in order to develop a rational approach to the treatment of chronic lung disease in CF which will ultimately require an ability to control the viscosity, rate of secretion and elimination of the secretions.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Biochemistry Study Section (BIO)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Schools of Pharmacy
Oklahoma City
United States
Zip Code
Damera, Gautam; Xia, Baoyun; Sachdev, Goverdhan P (2006) IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir Res 7:39
Damera, Gautam; Xia, Baoyun; Ancha, Hanumatha R et al. (2006) IL-9 modulated MUC4 gene and glycoprotein expression in airway epithelial cells. Biosci Rep 26:55-67
Hebbar, Vidya; Damera, Gautam; Sachdev, Goverdhan P (2005) Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer 5:124
Shankar, V; Pichan, P; Eddy Jr, R L et al. (1997) Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. Am J Respir Cell Mol Biol 16:232-41
Shankar, V; Gilmore, M S; Sachdev, G P (1995) Further evidence that the human MUC2 gene transcripts in the intestine and trachea are identical. Biochem J 306 ( Pt 1):311-2
Shankar, V; Gilmore, M S; Elkins, R C et al. (1994) A novel human airway mucin cDNA encodes a protein with unique tandem-repeat organization. Biochem J 300 ( Pt 2):295-8
Padhye, N V; Shankar, V; Reyes de la Rocha, S et al. (1994) Biophysical characterization of mucin components HTM-1 and HTM-2 from tracheobronchial secretions of cystic fibrosis patients. Biochim Biophys Acta 1209:56-60
Desai, V C; Shankar, V; de la Rocha, S R et al. (1993) Peptide mapping reveals differences in the non-glycosylated domains of cystic fibrosis and normal tracheobronchial mucins. Indian J Biochem Biophys 30:382-8
Desai, V C; Naziruddin, B; Graves, D C et al. (1991) Production and characterization of monoclonal antibodies to purified deglycosylated cystic fibrosis respiratory mucin: evidence for the presence of four immunologically distinct epitopes. Hybridoma 10:285-96
Padhye, N V; Naziruddin, B; Desai, V C et al. (1991) Physicochemical characterization of a minor mucin component from cystic fibrosis tracheobronchial secretions. Biochim Biophys Acta 1077:332-8

Showing the most recent 10 out of 14 publications